Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + venetoclax + obinutuzumab in relapsed/refractory follicular lymphoma
2016-005061-31Phase 2Completed
- Sponsor
- LYSARC
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, venetoclax and obinutuzumab in follicular lymphoma (FL), sponsored by LYSARC. Primary endpoint: Overall Metabolic Response Rate. Started Sep 2017; status: completed.
02
Drugs
atezolizumabvenetoclaxobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2016-005061-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005061-31.